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Abstract
Background: Long-term breast-cancer survivors have a highly elevated risk (1 in 6 at 20 years) of contralateral
second breast cancer. This high risk is associated with the presence of multiple pre-malignant cell clones in the
contralateral breast at the time of primary breast cancer diagnosis. Mechanistic analyses suggest that a moderate
dose of X-rays to the contralateral breast can kill these pre-malignant clones such that, at an appropriate Prophylactic
Mammary Irradiation (PMI) dose, the long-term contralateral breast cancer risk in breast cancer survivors would be
considerably decreased.
Aims: To test the predicted relationship between PMI dose and cancer risk in mammary glands that have a high risk
of developing malignancies.
Methods: We tested the PMI concept using MMTV-PyVT mammary-tumor-prone mice. Mammary glands on one
side of each mouse were irradiated with X-rays, while those on the other side were shielded from radiation. The
unshielded mammary glands received doses of 0, 4, 8, 12 and 16Gy in 4-Gy fractions.
Results: In high-risk mammary glands exposed to radiation doses designed for PMI (12 and 16 Gy), tumor incidence
rates were respectively decreased by a factor of 2.2 (95% CI, 1.1-5.0) at 12 Gy, and a factor of 3.1 (95% CI, 1.3-8.3)
at 16 Gy, compared to those in the shielded glands that were exposed to very low radiation doses. The same pattern
was seen for PMI-exposed mammary glands relative to zero-dose controls.
Conclusions: The pattern of cancer risk reduction by PMI was consistent with mechanistic predictions. Contralateral
breast PMI may thus have promise as a spatially targeted breast-conserving option for reducing the current high risk
of contralateral second breast cancers. For estrogen-receptor positive primary tumors, PMI might optimally be used
concomitantly with systemically delivered chemopreventive drugs such as tamoxifen or aromatase inhibitors, while
for estrogen-receptor negative tumors, PMI might be used alone.
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Introduction
Breast cancer is one of the most common types of cancer in
the US, and as many as one in eight women may develop
breast cancer during their lifetime [1]. Long term survival after
breast cancer diagnosis has increased markedly in the last
decade, with the mean 15-year relative survival in the US now
77% [1]. It is therefore highly appropriate that increasing
attention is being paid to the issue of breast cancer
survivorship and to the issue of second breast cancers [2]. In
particular, long term studies suggest that a 20-year breast
cancer survivor has about a 1 in 6 risk of developing a
contralateral second breast cancer [3,4], which is several-fold
higher than primary breast cancer incidence among age-
matched healthy women [5,6]. As a result of these long-term
risks, between 10% and 20% of all breast cancer patients in
the US currently undergo prophylactic contralateral
mastectomy [7-9].
For estrogen-receptor positive tumors, adjuvant tamoxifen
reduces contralateral breast cancer risks by as much as 40%
[10] - which for long-term survivors represents a risk reduction
from about 16% to 10%, still a disturbingly high risk. Tamoxifen
is not considered effective for the ~30% of breast cancers
which are estrogen-receptor negative [6,11,12]. A further
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incremental improvement for postmenopausal women is likely
obtainable with aromatase inhibitor drugs [13], though again
largely for estrogen-receptor positive primary cancers [12].
Both classes of chemopreventive drugs have significant side
effects: gynecological and thromboembolic in the case of
tamoxifen, and reduced bone mineral density in the case of
aromatase inhibitors. In summary, there is a need for
alternative approaches to further reduce the long term risks of
contralateral breast cancer in breast cancer survivors.
The general concept behind chemopreventive approaches is
that carcinogenesis is a multi-stage process involving the
gradual accumulation of pre-malignant clones, with
chemopreventive drugs intervening at one or more stages in
this process [14]. We have previously proposed [15], and here
we provide some experimental validation for, an alternative (or
concomitant) approach for reducing contralateral breast cancer
risks – though with the same overall rationale, to intervene in
the multi-stage processes leading here to contralateral breast
cancer. Specifically, an intermediate dose of ionizing radiation,
which is an effective and spatially targeted cytotoxic agent, has
the potential to kill essentially all the pre-existing pre-malignant
cells in the contralateral breast of a breast cancer patient, and
thus significantly reduce the incidence of contralateral breast
cancers. In such an approach it is not necessary to identify
these pre-existing pre-malignant cells, in that radiation-induced
cell killing is largely a statistical process: Assuming that these
pre-existing pre-malignant cells are far fewer in number than
the healthy human cells, which will always be the case, the
suggestion is that they can be essentially all killed with a
moderate dose of radiation that produces minimal normal-
tissue complications [15].
Of course ionizing radiation is also carcinogenic, and can
induce new breast tumors [16,17].The net effect, therefore, of
irradiating a breast containing significant numbers of pre-
existing pre-malignant clones (such as the contralateral breast
of a breast-cancer patient) will be dominated by the balance of
two opposing processes: 1) killing of pre-existing pre-malignant
cell clones, leading to reduced background breast cancer risk,
versus 2) net induction of new pre-malignant cell clones,
leading to radiation carcinogenesis. One of the main rationales
behind the current work is that the risk of radiation-induced
breast-cancer decreases sharply with age at irradiation [16-18],
becoming very low for women aged >50, who constitute the
majority of breast cancer patients [17,18]. This observation is
consistent with findings that breast cancer radiotherapy does
not appear to increase the net risk of new (genetically
independent of the primary tumor) breast cancers in the
irradiated ipsilateral (affected) breast [17,19], and may even
decrease it [20,21].
In fact, a mechanistically-based analysis [15] of the time-
dependence of new (non-recurrent) breast cancers in the
ipsilateral breast suggests that, even at the comparatively high
radiotherapeutic doses generally used for breast-cancer
radiotherapy (50 Gy in 2 Gy fractions to the entire affected
breast), net induction of pre-malignant cells is essentially
neutral: most pre-existing pre-malignant cells are killed, and a
similar number of new ones are induced.
The ipsilateral breast requires a high radiation dose in order
to eradicate large numbers of remaining primary tumor cells.
However the reasoning here suggests [15] that a much lower
radiation dose would still be sufficient to kill the smaller number
pre-existing pre-malignant cells, which are independent of the
primary tumor – and of course a much lower radiation dose
would be associated with much lower risks for inducing new
cancers or normal-tissue complications. Thus, irradiating the
contralateral breast of breast cancer patients with such a
moderate radiation dose might be an effective option for safely
reducing contralateral breast cancer risks in breast cancer
survivors [15]. We have termed this novel application of
reduced-dose radiotherapy for contralateral breast cancer
prevention “Prophylactic Mammary Irradiation” (PMI) [15].
Although the number of pre-malignant target cells in the
contralateral breast is not well defined, because the
dependence of the required radiation dose on this number is
logarithmic rather than linear [22], any realistic number of pre-
malignant cells (e.g. up to several thousand) could be killed by
a dose of around 20-25 Gy in 10 fractions [3]. If the PMI dose is
chosen appropriately, the benefit in terms of cancer risk
reduction for breast cancer survivors would be expected to
significantly outweigh the small risks of radiation-induced
cancer or other radiation-induced normal-tissue complications
[15].
Figure 1 shows a schematic of the expected overall cancer
risk as a function of PMI dose, for a breast at high initial risk of
a future cancer, i.e. containing a significant number of pre-
existing pre-malignant cells. At low doses, only a few pre-
existing pre-malignant cells will be killed and the mutagenic
effects of the radiation may cause a net increase in cancer risk.
As the dose increases, killing the pre-existing pre-malignant
cells will dominate, and the overall cancer risk is expected to
decrease. Finally, when all the pre-existing pre-malignant cells
have been killed, still further radiation doses would be expected
to increase the risks of cancer and/or normal tissue
complications.
Thus, PMI of the whole contralateral breast, performed at the
same time as standard post-lumpectomy radiotherapy to the
ipsilateral breast, and with an optimally chosen intermediate
radiation dose, might be a potentially breast-conserving option
to significantly decrease the high second cancer risks in the
contralateral breast of long-term breast cancer survivors [15].
Because radiation-induced cell killing is likely to be
independent of estrogen receptor status, this approach would
be expected to be equally effective for estrogen receptor
positive or negative tumors. It is emphasized that this concept
would only be useful for an organ at high risk (i.e. containing
large numbers of pre-malignant cells), and for an organ where
the radiation-induced cancer risk is low. The contralateral
breast of a breast-cancer survivor over the age of about 50
meets these criteria.
Here we have tested the PMI hypothesis in an animal model
for high-risk breast cancer – the FVB/N-Tg(MMTV-
PyVT)634Mul/J (abbreviated as MMTV-PyVT) female
transgenic mouse [23]. Our goal is to investigate whether the
predicted pattern of cancer risk with increasing PMI dose, as
illustrated in Figure 1, holds for a high-risk mammary gland.
Prophylactic Contralateral Breast Irradiation
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MMTV-PyVT mice develop multiple mammary tumors at an
early age (typically <100 days) due to the polyoma virus T-
antigen (PyVT) driven by the mouse mammary tumor virus
(MMTV) promoter. We investigated the effects of various doses
of mammary irradiation (up to 16 Gy delivered in 4 Gy
fractions) on tumor development in these mice, and show that
the expected breast cancer risk pattern with increased dose
(Figure 1) was indeed apparent: specifically, a small increase
in cancer risk at low radiation doses, followed by a decrease in
cancer risk at PMI-relevant doses, with the mammary tumor
incidence rate reduced by a factor of about three.
Materials and Methods
This study was approved by Columbia University IACUC,
under Animal Care Protocol AC-AAAD3951, and all mouse
work was performed in accordance with IACUC guidelines.
Mammary tumor incidence rates were measured as a function
of radiation dose in: 1) irradiated mammary glands, 2) shielded
mammary glands exposed only to low doses of scattered
radiation, and 3) unexposed control animals.
Transgenic Mice
To conduct proof of principle experiments regarding the PMI
hypothesis, we selected the FVB/N-Tg(MMTV-PyVT)634Mul/J
female mouse (MMTV-PyVT) [23], from the Jackson
Laboratory. In this mouse strain, an oncogene derived from the
polyoma virus is expressed under hormonal regulation in
mammary gland tissues, driven by the mammary tumor virus
(MMTV) promoter [23]. Female transgenic mice of this strain
begin to develop palpable mammary tumors in early adulthood
(the median age of tumor onset is 66 days), and all the mice
will eventually develop tumors [24]. Therefore, the progression
from pre-malignant to malignant breast disease, which occurs
in breast cancer patients, is mimicked by this mouse model, but
in a more aggressive and rapid manner. This allows proof of
principle testing of PMI to be conducted in vivo, minimizing
mouse numbers and follow-up time.
Mouse Irradiation Geometry
The near hemi-body irradiation geometry used here is
illustrated in Figure 2. One side of each mouse, as well as the
head, was shielded with 12.7 mm of lead. This geometry allows
most of the body to be protected, exposing only one side of the
thorax and abdomen and five mammary glands. The left side
was unshielded in half of the mice, and the right side in the
Figure 1.  Schematic of radiation dose-effects on breast-cancer risk in the contralateral breast of breast cancer
patients.  The overall cancer risk is determined by a balance between killing of pre-existing pre-malignant cell clones vs. induction
of new pre-malignant cell clones by radiation. The hypothesis underlying the present work is that there is a dose “window” at
intermediate doses where killing of pre-existing pre-malignant clones dominates, thus reducing overall cancer risks.
doi: 10.1371/journal.pone.0085795.g001
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other half. This partial-body irradiation geometry has been
described in more detail elsewhere [25]; the main
radiosensitive organs, such as the bone marrow, lungs,
intestinal tract, and ovaries, are protected on at least one side
of the body, which allows the irradiated animals to remain in
good health for long enough after irradiation to develop
mammary tumors. In particular, allowing one ovary to be
shielded from high-dose radiation exposure was designed to
minimize indirect effects of radiation on mammary
carcinogenesis through effects on ovarian hormone production.
Choice of Radiation Doses
One hundred female MMTV-PyVT mice, divided into 5
groups of 20 mice each, were used. The mice were between
41 and 43 days old at the start of irradiation. Each group
respectively received total x-ray doses to the unshielded
mammary glands of 0, 4, 8, 12 and 16 Gy, delivered in 4-Gy
fractions. The maximum number of fractions per day was two,
6 hours apart. In summary, the unexposed control mice
received a single sham-irradiation, the 4 Gy exposed mice
received a single irradiation with 4 Gy, and the 8 Gy exposed
mice received two 4 Gy irradiations 6 hours apart on the same
day. The 12 Gy exposed mice received two 4 Gy irradiations 6
hours apart on the first day, and a third 4 Gy irradiation on the
second day. The 16 Gy exposed mice received two 4 Gy
irradiations 6 hours apart on the first day, and two more 4 Gy
irradiations 6 hours apart on the second day.
The two highest doses (12 and 16 Gy in 4-Gy fractions) were
designed to be in the range that would sterilize most or all of
the pre-existing pre-malignant and/or early malignant cells in
Figure 2.  Shielding geometry for mouse mammary
irradiations.  Schematic ventral view of a partially lead-
shielded mouse, with mammary glands outlined by dotted lines.
Unshielded mammary glands on one side of the mouse
received the full radiation dose, while the mammary glands on
the lead-shielded side received a much lower dose – about 6%
of the unshielded dose.
doi: 10.1371/journal.pone.0085795.g002
each mouse mammary gland (roughly estimated to number
several thousand in female mice [26,27]), which are the likely
progenitors of the mammary tumors. These two highest doses
(12 and 16 Gy in 4-Gy fractions), thus designed to be the
putative PMI doses, are also approximately equivalent in terms
of cell killing to the originally proposed [14] clinical PMI doses
of 17 to 20 Gy in 10 fractions.
Mouse Dosimetry
The x-ray irradiations were carried out using an XRAD-320
irradiator (Precision X ray, North Branford, CT) operated at 320
kVp and 12.5 mA, with a filter composed of 1.5 mm Al, 0.25
mm Cu and 0.75 mm Sn. The dose rate was 0.86 Gy/min.
Immediately prior to irradiation, the mice were anesthetized
with a 0.2 ml intraperitoneal injection of a solution of 10 mg/ml
ketamine and 1 mg/ml xylazine. Control mice, receiving 0 Gy,
were anesthetized and sham-irradiated.
Doses were measured using microMOSFET [28] solid-state
dosimeters (Best Medical, Ottawa, Ontario, Canada) inserted
into a tissue-equivalent mouse phantom. Due to x-ray scatter,
the shielded contralateral mammary glands received an
average dose of approximately 6% of the corresponding doses
to the unshielded mammary glands. This ratio of doses in the
shielded vs. unshielded mammary glands is similar to the ratio
of doses in the contralateral vs. the irradiated breast in human
breast radiotherapy [29].
Mouse Carcinogenesis Assay
The mice were maintained with 50 mg/kg amoxicillin in the
drinking water, and their health and body weights were
monitored regularly. After irradiation, the mouse mammary
glands were palpated at 2-3 day intervals. Appearance times
and the sizes of mammary tumors were recorded. Mice were
sacrificed according to Columbia University animal care
guidelines when they met either of the following criteria: tumor
diameter >20 mm, tumor size exceeding 10% of body weight,
tumor ulceration, debilitating diarrhea, progressive dermatitis,
rough hair coat, hunched posture, lethargy or persistent
recumbence, coughing, labored breathing, neurologic signs
(e.g. circling, head pressing, seizuring), bleeding from any
orifice, self-induced trauma, and any condition interfering with
eating or drinking (e.g., difficulty with ambulation). All mice
eventually developed mammary tumors, and most had multiple
tumors. The first tumor to present was invariably the one which
caused the mouse to be sacrificed when it grew to a large size,
and tumors which appeared later were still small at the time of
sacrifice. Consequently, the incidence rate of the first detected
tumor was selected as the most relevant endpoint in this study,
and these data are presented here.
Statistical Analysis
The goal of this study was to assess how radiation dose
affected the cumulative incidence rate (per mouse-day at risk)
of the first detected palpable mammary tumors. This was done
by comparing the cumulative tumor incidence rates in each
radiation dosage group, on each mouse side (unshielded or
shielded), with the rate in the unirradiated control group, using
Poisson regression, as implemented by the WinPepi software
Prophylactic Contralateral Breast Irradiation
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package [30]. The data were consistent with Poisson
assumptions, as suggested by the strong correlation (0.98)
between standardized residuals and normal scores, and by the
p-value (0.14) for the score test for the total model.
Cumulative tumor incidence rates on different mouse sides
were also compared within each radiation dosage group, using
the 2-tailed mid-P approach [30] with Bonferroni correction for
multiple pairwise comparisons. The 95% confidence intervals
presented here for the incidence rate ratios were produced by
the mid-P approach, and were similar to those generated by
the Poisson regression approach mentioned above, and also
by Fisher’s exact test. This same mid-P approach was also
used to estimate 95% confidence intervals for the cumulative
tumor incidence rate for each mouse side in each radiation
dosage group.
The potential presence of a monotonic trend in tumor
incidence rate as function of radiation dose was evaluated by
the Poisson trend statistic (Eq. 3.12 in Ref. [31]). Temporal
trends in the accumulation of mammary tumors in each
radiation dosage group, and on each mouse side, were
analyzed by the logrank test.
All the data pertaining to the mice used in this study,
including body weights, dates of irradiation, tumor detection
and sacrifice, are available upon request.
Results
Each irradiated mouse received a fractionated radiation dose
(varying from 4 to 16 Gy in different mice) to the unshielded
mammary glands, and a very much lower dose (<1 Gy) to the
shielded glands (0.2-0.9 Gy) caused by x-ray scatter. As seen
in earlier studies of radiation-induced mammary cancer [32],
the temporal kinetics of mammary tumor appearance showed
no significant dose dependence: among the different dose
groups (including the zero-dose and the scatter-dose groups)
the median times of first detectable tumor appearance ranged
only from 34.0 to 37.5 days post irradiation (or sham
irradiation).
By contrast, the cumulative tumor-incidence rates (per
mouse-day at risk) showed a clear dose response. Both
relative to the zero dose controls, and relative to the
corresponding mammary glands that received only scattered
doses, tumor incidence rates initially increased with increasing
dose to the irradiated mammary gland, but then decreased at
higher doses to below the background levels. These results are
summarized in Tables 1 and 2 and Figure 3.
We focus here on comparisons between tumor incidence
rates in the PMI-irradiated mammary glands and in the
corresponding shielded mammary glands; as described above,
this is designed to model a comparison of cancer rates in a
human contralateral breast exposed to PMI vs. cancer rates in
the same breast receiving a typical scatter dose after standard
radiotherapy to the ipsilateral breast. At the doses which were
designed to be relevant for PMI (12 Gy and 16 Gy, see above)
the tumor incidence rates in the unshielded PMI-exposed
glands were significantly lower than those in the shielded
glands: the rate ratios between the PMI-exposed glands and
the shielded glands were 0.45 (95% CI: 0.20-0.98, 2-tailed p
value: 0.04) at 12 Gy and 0.32 (95% CI: 0.12-0.77, 2-tailed p
value: 0.009) at 16 Gy (Table 2).
These same patterns were apparent for the tumor rates in
the PMI-exposed glands relative to zero-dose controls (Table
2). Although here statistical significance was not reached for
any dosage group alone, the Poisson trend statistic [32]
Table 1. Mammary tumor incidence rates as a function of
radiation dose, for zero dose controls, lead-shielded glands,




Tumor incidence rate (per
1,000 mouse-days)
   Rate 95% CI*
Zero dose
controls 0 1 14.2 9.4, 20.6
Shielded glands 0.23 1 14.2 7.7, 24.0
 0.46 2 12.0 6.3, 20.9
 0.69 3 22.4 14.1, 33.9
 0.92 4 22.1 13.7, 33.9
Unshielded
irradiated glands 4 1 16.5 9.4, 27.0
 8 2 15.3 8.7, 25.1
 12 (PMIdose) 3 10.2 4.9, 18.5
 16 (PMIdose) 4 7.0 2.8, 14.5
The last two rows refer to glands irradiated at the doses which were designed to be
relevant for PMI (12 and 16 Gy).
* The 95% CIs were estimated using the mid-P approach [30].
doi: 10.1371/journal.pone.0085795.t001





Tumor incidence rate ratio vs.
shielded scatter dose
Tumor incidence rate ratio
vs. zero dose controls
 Ratio 95% CI* p-value* Ratio 95% CI* p-value**
4 1.17 0.53,2.58 0.70 1.16 0.66,1.90 >0.50
8 1.27 0.57, 2.89 0.56 1.09 0.61,1.77 >0.50
12 (PMI




dose) 0.32 0.11, 0.77 0.009 0.49
0.20,
1.02 0.44
Shown are rates in unshielded irradiated mammary glands, compared with lead-
shielded mammary glands that were exposed only to low scatter doses, and also
compared with zero-dose controls. The last two rows refer to glands irradiated at
the doses which were designed to be relevant for PMI (12 and 16 Gy).
* The 95% CIs and 2-tailed p-values were estimated using the mid-P approach
[30].
** Bonferroni correction applied to adjust for multiple comparisons.
doi: 10.1371/journal.pone.0085795.t002
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suggested a highly significant (p = 0.00012) decreasing trend in
tumor incidence rate over the dose range from 4 Gy to 16 Gy.
Discussion
The measured dose response patterns (Tables 1-2, and
Figure 3) are consistent with the expectations underlying the
PMI hypothesis schematized in Figure 1. Specifically, at low
doses there is an increase in radiation-induced breast cancer,
presumably because few pre-existing pre-malignant cells are
killed, and more new ones are induced. However, at the doses
designed to be in the optimal PMI dose region (12 and 16 Gy),
the overall breast cancer incidence rate was lower than in the
controls, as predicted. Specifically, the optimal PMI dose in this
study (16 Gy in 4 fractions) reduced the high background
mammary tumor incidence rate by a factor of about three.
While there are similarities, there are of course differences
between the high-risk animal breast cancer model used here
and the contralateral breast in a breast cancer patient. Firstly,
the mice were irradiated at an earlier time of life (early puberty)
compared to most women (who develop breast cancer at a
median age ~60): In fact both for rodents [33] and humans
[16,18], radiation-induced breast cancer risks fall off sharply for
age at exposure in middle age. Younger mice were used in this
validation study explicitly to enhance any potential radiation-
induced carcinogenic effects: that the prophylactic effects at
PMI doses dominated these carcinogenic effects even in a
young mammary gland (where these carcinogenic effects are
maximal) suggests that in older mammary glands the cancer
risk reduction from PMI may be even more pronounced.
Secondly, it is unclear whether the relevant cells in the
mouse model should be considered as pre-malignant or fully
malignant, or perhaps a combination of these; this should not,
however, affect the dose-effect patterns seen here, as killing of
either would be expected to reduce cancer risk – and indeed
the target cells for contralateral breast cancer in humans are
also likely to be heterogeneous in their development.
Figure 3.  Tumor incidence rate ratios for tumors in unshielded irradiated mammary glands, compared to lead-shielded
glands.  The doses which were designed to be potentially relevant for PMI are 12 and 16 Gy. The comparison here is with lead-
shielded contralateral mammary glands that were exposed only to low scatter doses – about 6% of the unshielded dose. Error bars
represent 95% CIs estimated using the mid-P approach [30].
doi: 10.1371/journal.pone.0085795.g003
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With these caveats, the results shown here are consistent
with the predicted pattern of cancer risks in the PMI dose
range. Specifically, we have provided proof-of-principle
experimental confirmation that there is likely to be a “window of
opportunity” in PMI dose (schematized in Figure 1) situated
between low doses, where radiation-induced cancer is
expected to dominate, and high doses, where both radiation-
induced carcinogenesis and/or radiation-induced normal tissue
damage will dominate: In this PMI intermediate-dose window
the potential to inactivate essentially all the pre-existing pre-
malignant cells in the high-risk breast is expected to dominate.
This conclusion is consistent with recent evidence from a
randomized control trial comparing intraoperative electron
radiotherapy with conventional whole-breast external beam
radiotherapy [34]. The trial showed that whole-breast irradiation
was more effective at preventing new ipsilateral breast tumors,
presumably because it kills pre-malignant cells in the entire
breast, whereas intraoperative electron radiotherapy, which
generates a cytotoxic dose mainly close to the tumor,
presumably could not eliminate more distant pre-malignant
breast cells.
Contralateral whole breast PMI may thus have promise as a
spatially-targeted breast-conserving option for reducing the
current high risk of contralateral second breast cancers in long-
term breast cancer survivors. The potential efficacy of PMI is
likely to be independent of estrogen receptor status: thus for
estrogen-receptor positive primary tumors, PMI might optimally
be used concomitantly with systemically delivered
chemopreventive drugs such as tamoxifen or aromatase
inhibitors, while for estrogen-receptor negative tumors, PMI
might be used alone.
Should PMI prove successful, the potential impacts could be
major. For example, there are currently more than 2.6 million
breast cancer survivors alive in the US [1]: applying typical
contralateral breast cancer incidence patterns [3] to this
population suggests that about 160,000 of these patients will
develop a contralateral breast cancer. If PMI reduced
contralateral breast cancer incidence by 3-fold, as was the
case in the rodent data shown here, approximately 100,000
breast cancer cases might be prevented.
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